1/69
Comprehensive practice flashcards for Clinical Study Monitoring I covering lecture principles, GCP guidelines, monitor responsibilities, source record criteria, and tutorial case studies.
What is the definition of clinical trial monitoring according to Good Clinical Practice (GCP)?
The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).
What are the three core purposes of clinical trial monitoring?
1) To verify that the rights and well-being of human participants are protected; 2) To verify that reported trial data are accurate, complete, and verifiable from source records; 3) To verify that the conduct of the trial complies with the currently approved protocol/amendment(s), GCP, and applicable regulatory requirement(s).
Who holds the primary responsibility for ensuring that clinical trials are adequately monitored?
The sponsor.
What trial characteristics must the sponsor consider when determining the appropriate extent and nature of monitoring?
The objective, purpose, design, complexity, blinding, size, investigational product (IP) safety profile, and endpoint of the trial.
At what stages of a clinical trial does monitoring occur?
Before the trial (initial visit), during the trial (intermediate visit), and after the trial (closing visit).
Where is on-site monitoring conducted?
At the sites at which the clinical trial is being conducted.
What monitoring strategy options may a sponsor choose from?
On-site monitoring, a combination of on-site and centralized (remote) monitoring, or centralized monitoring alone.
How is the frequency of clinical trial monitoring activities determined?
Based on identified risks.
Where must the sponsor document the rationale for their chosen monitoring strategy?
In the monitoring plan.
What is centralized (remote) monitoring?
A timely, remote evaluation of accumulating data, supported by appropriately qualified and trained persons (such as data managers, biostatisticians, and CRAs).
How does centralized monitoring support and interact with on-site monitoring?
It provides additional monitoring capabilities, complements on-site monitoring, and can reduce the extent and/or frequency of on-site monitoring.
What is the primary analytical mechanism used in centralized monitoring to identify systemic or site-specific issues?
Centralised data analytics.
What specific data discrepancies can centralized monitoring identify?
Missing data, inconsistent data, data outliers, unexpected lack of variability, and protocol deviations.
How can centralized monitoring evaluate data trends across a study?
By examining data trends such as the range, consistency, and variability of data within and across clinical sites.
How does centralized monitoring detect data manipulation and integrity issues?
By evaluating systematic or significant errors in data collection and reporting at a site or across sites, as well as detecting potential data manipulation or data integrity problems.
How is centralized monitoring used to target on-site monitoring activities?
It analyzes site characteristics and performance metrics to select specific sites and/or processes for targeted on-site monitoring.
Who is involved in trial monitoring on both the sponsor and site sides?
The sponsor appoints the Monitor (Clinical Research Associate / CRA); the site is represented by the Principal Investigator, Clinical Research Coordinator (CRC), and other site team members.
What qualification requirements must a trial monitor fulfill according to SG-GCP 5.18.2?
The monitor should be appropriately trained, possess the scientific and/or clinical knowledge needed to monitor the trial adequately, and have their qualifications documented.
In the ABC Pharmaceutical project manager scenario for a Vitamin D fatigue trial at NUH, what qualifications should be sought when hiring a CRA?
A CRA with documented training, relevant clinical or scientific knowledge, familiarity with GCP and local regulatory requirements, and trial monitoring experience.
What seven essential areas or documents must a trial monitor be thoroughly familiar with?
The investigational product(s), the protocol, written informed consent form, any other written information to be provided to participants, the sponsor's SOPs, GCP, and applicable regulatory requirements.
What is the monitor's role regarding communication between the sponsor and the site?
The monitor acts as the main line of communication between the sponsor and the investigator.
What must the monitor verify regarding the investigator's resources and site infrastructure?
Verify the qualifications and resources of the investigator and verify that the site has adequate facilities and staffing to conduct the trial properly.
What must the monitor verify regarding investigational product (IP) storage and supply levels?
Verify that storage times and conditions of the IP are acceptable, and that supplies are sufficient throughout the trial.
Which specific log does a monitor review to verify that IP storage conditions remained acceptable?
The Temperature Monitoring Log.

What clinical trial monitoring form is shown in this image?
Temperature Log (or Temperature Monitoring Log).
What specific temperature readings and entries are recorded on a trial Temperature Log?
Date, Time, Temperature (∘C), Max (∘C), Min (∘C), Name, and Signature.

What form is illustrated in this image for tracking investigational drug dispensing and returns?
Sample Drug Inventory and Accountability Log.
What must the monitor verify regarding the population receiving the investigational product and its dosing?
Verify that the IP(s) are supplied only to eligible participants and at the protocol-specified dose(s).
Which documents must the monitor review to confirm that the IP was dispensed only to eligible subjects at protocol-specified doses?
Inclusion/exclusion (I/E) criteria documentation, the Drug Dispensing Log, and the Medication Administration Record.
What handling instructions must be provided to participants, investigators, and site staff regarding the IP?
Necessary instructions on properly using, handling, storing, returning, and disposing of the investigational product.
Which documents verify that the receipt, use, and return of the IP at trial sites are controlled and documented adequately?
The Drug Accountability Log and Drug Dispensing Log.
What must the monitor verify regarding the disposition of unused investigational product?
Verify that the disposition of unused IP at the trial sites complies with applicable regulatory requirements and is in accordance with the sponsor's instructions.

What document is depicted in this image for recording the destruction of trial drug supplies?
Drug Destruction Log (or Example Drug Destruction Log).
What confirmation statement does authorized site personnel sign on the Drug Destruction Log?
"I can confirm that the drug supplies as listed above have been destroyed according to GMP/GCP guidelines."
What must the monitor verify regarding protocol versions and institutional approvals?
Verify that the investigator follows the approved protocol and all approved amendments (with IRB/EC approval).
What is the GCP timing rule regarding written informed consent and trial procedures?
Written informed consent must be obtained BEFORE each participant's participation in the trial; no procedure should be done without informed consent.
What document does the monitor review to ensure only authorized personnel are performing study-related duties?
The Site Delegation Log.
Which source records does a monitor check to verify that the investigator is enrolling only eligible participants?
Patient's medical records, laboratory results, and other relevant source documents confirming inclusion/exclusion criteria.
What is the monitor's duty regarding participant enrollment numbers?
To report the participant recruitment progress and rate to the sponsor.
What standards must investigator submissions, notifications, and reports meet as verified by the monitor?
They must be accurate, complete, timely, legible, dated, and clearly identify the trial.
What data elements must a monitor cross-check between Case Report Form (CRF) entries and source records?
Data entries (missing, inconsistent, outliers, trends), dose/therapy modifications, adverse events (AEs), concomitant medications, intercurrent illnesses, protocol deviations, and withdrawals/dropouts.
What procedure must be followed if the monitor detects CRF errors, omissions, or illegibility?
Inform the investigator and ensure that appropriate corrections, additions, or deletions are made, dated, explained (if necessary), and initialed by the investigator or authorized trial staff.
What are the monitor's responsibilities concerning Adverse Events (AEs)?
Ensure all AEs are appropriately reported within the timelines required by GCP, the protocol, the IRB/IEC, regulatory authorities, and the sponsor.
What action must a monitor take when protocol, SOP, GCP, or regulatory deviations are detected?
Communicate the deviations to the investigator and take appropriate action designed to prevent recurrence of the detected deviations.
What is a monitoring report?
A written report submitted to the sponsor by the monitor after each trial-site visit or trial-related communication.
What administrative details must be documented in every monitoring report?
Date, site, name of the monitor, name of the investigator, and other individuals contacted.
What substantive findings and conclusions must a monitoring report contain?
A summary of what the monitor reviewed, significant findings/facts, deviations and deficiencies, actions taken or recommended to secure compliance, and conclusions.
Who must document the review and follow-up of the monitoring report for the sponsor?
The sponsor's designated representative.
Why is timely submission of monitoring reports after a site visit essential?
It allows the sponsor's management and oversight staff to promptly review trial progress, resolve safety concerns, address deviations, and implement corrective actions before issues escalate.

What form is shown in this image for logging monitor visits at a clinical trial site?
Monitoring Log.
What examples of monitoring activities are recorded under the 'Description of Monitoring Activity' on a Monitoring Log?
Pre-site, initiation, routine, and external audit.
What core components must be outlined in a clinical trial monitoring plan?
The monitoring strategy, monitoring responsibilities of all parties involved, various monitoring methods used, and the rationale for the chosen methods.
What specific aspects must the monitoring plan emphasize and pay particular attention to?
It should emphasize the monitoring of critical data and processes (participant safety, primary/key secondary endpoints), and aspects that are not routine clinical practice and require additional training.
How should trial processes performed outside the investigator site be addressed in the monitoring plan?
Processes performed outside the investigator site (such as central image reading facilities and central laboratories) should be specifically addressed in the monitoring plan.
How do Spriet & Dupin-Spriet (2005) define a source record?
Any original document or data involving a patient enrolled in a clinical trial, collected independently or not of data on the trial, established for medical follow-up, which can be compared to data transcribed in the case report form.
What are the four fundamental characteristics of source records?
1) Independence; 2) Original; 3) Contemporaneous; 4) Nominative.
What does the 'Independence' characteristic of a source record mean?
The records are part of the patient's medical records, and some of them would have existed even if the patient had not entered the clinical trial.
What formats are explicitly stated NOT to qualify as an 'Original' source record?
A photocopy, a duplicate, a micro-copy, or an electronic file after having been "scanned".
What does the 'Contemporaneous' characteristic require of source documents?
The document must record data at the time of execution and must not be pre-dated, since pre-dating is considered data falsification.
What does the 'Nominative' characteristic of a source record require?
The document must list the patient's personal identity clearly.
List five valid examples of source records accepted in clinical trials.
Hospital medical records, nursing notes/hospital charts, forms containing laboratory results, ECG tracings, X-rays and interpretations, medication administration records, patient self-evaluation diaries, and certified true copies.
In the Brad Low tutorial exercise, can an A&E admission record dated 30 Apr 2025 be used as a source record for a trial joined on 1 May 2025?
Yes, it is an original, independent medical record documenting his hospital admission and medical history.
In the Brad Low exercise, can a hospital laboratory haematology report dated 1 May 2025 with his name and IC be used as a source record?
Yes, it is original, contemporaneous, and nominative.
In the Brad Low exercise, can a photocopy of an ECG tracing stamped with 'certified true copy' be accepted as a source record?
Yes, a properly certified true copy is legally recognized to serve as an acceptable equivalent to an original source document.
In the Brad Low exercise, can a standard uncertified photocopy of a GP's referral letter be used as a source record?
No, because an uncertified photocopy violates the requirement that a source record must be an original document.
In the Brad Low exercise, can the Case Report Form (CRF) for his first visit be used as a source record?
No, the CRF is a data collection tool used to transcribe and report data to the sponsor; it is not the original medical source document.
In the Brad Low exercise, why are an uncertified scanned copy of an X-ray and a smartphone photograph of a lab result rejected as source records?
Because source records must be original; ordinary scanned files and informal pictures lack certified authenticity and do not meet original source standards.
In the NYPharma diabetes case study, what are the primary benefits of implementing remote monitoring across 25 global sites?
Real-time visibility into patient vitals/labs, automated early alerts for deviations/safety issues, reduced travel expenses/time, centralized data analytics across sites, and improved monitoring efficiency.
What challenges might NYPharma encounter when relying on remote monitoring and home wearables across five countries?
Data privacy and cross-border encryption regulations, technical downtime/connectivity issues, variability in site technological literacy, patient compliance with wearable devices, and the inability to physically inspect drug storage facilities.
What are the potential consequences of significant delays in submitting monitoring reports?
Unresolved subject safety issues, unchecked recurrence of protocol deviations, delayed corrective and preventive actions (CAPA), potential compromise of trial data integrity, and regulatory non-compliance during audits.